Table 2.

Multivariable models of KSHV prevalence and incidence

	OR* (prevalence)	[95%	CI#]	p value	IRR+ (incidence)	[95%	CI]	p value
Socio demographic
Male gender	2.43	2.04	2.90	<0.001	2.30	1.69	3.14	<0.001
Caucasian race	1.20	1.06	1.36	0.004	1.35	1.11	1.63	0.003
Age (years)
<30	ref.				ref.
30-39	1.32	1.12	1.55	0.001	0.76	0.59	0.97	0.025
40-49	1.33	1.12	1.58	0.001	0.65	0.50	0.85	0.002
≥50	1.03	0.82	1.28	0.806	0.57	0.40	0.81	0.002
IDU	0.72	0.59	0.88	0.001	1.17	0.86	1.60	0.312
Residence in NE or W region	1.20	1.35	1.71	<0.001	1.06	0.87	1.29	0.561
calendar time
1997-2001	ref.				ref.
2002-2007	1.26	1.11	1.43	<0.001	1.82	1.48	2.23	<0.001
Antiherpesvirus drugs
Anti-HSV	0.96	0.81	1.15	0.650	0.84	0.63	1.11	0.225
Anti-CMV-like	0.49	0.22	1.09	0.080	0.82	0.26	2.56	0.729
Baseline CD4 count (cell/μL)
<200	ref.				ref.
200-349	1.50	1.29	1.74	<0.001	1.08	0.85	1.37	0.534
350-499	1.56	1.30	1.87	<0.001	1.10	0.82	1.47	0.523
≥500	1.40	1.11	1.77	0.005	0.97	0.67	1.41	0.866
Baseline Log HIV-1 VL	1.09	0.99	1.19	0.067	1.07	1.00	1.15	0.067
cART	n/a
assigned PI					0.91	0.75	1.10	0.315
CD4 response	n/a
No CD4 increase					ref.
Any CD4 increase					0.60	0.43	0.80	0.001

^*OR, odds ratio

^#CI, confidence interval

⁺IRR, incidence rate ratio